login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VERRICA PHARMACEUTICALS INC (VRCA) Stock News
USA
- NASDAQ:VRCA -
US92511W2070
-
Common Stock
4.15
USD
-0.08 (-1.89%)
Last: 10/17/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VRCA Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
12 days ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
a month ago - By: Benzinga
- Mentions:
BFLY
CLLS
ADAP
CTXR
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 months ago - By: Benzinga
What to Expect from Verrica Pharmaceuticals's Earnings
a month ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
a month ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: The Motley Fool
Verrica Posts Profit in Fiscal Q2
2 months ago - By: Zacks Investment Research
- Mentions:
IGC
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
2 months ago - By: Zacks Investment Research
- Mentions:
SLNO
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
2 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
3 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
4 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
4 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
5 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
5 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
5 months ago - By: Zacks Investment Research
- Mentions:
IPSC
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
5 months ago - By: Verrica Pharmaceuticals Inc.
- Mentions:
TVTX
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
5 months ago - By: Zacks Investment Research
- Mentions:
ASRT
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
6 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
6 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
6 months ago - By: Zacks Investment Research
- Mentions:
AMRX
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
6 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
6 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
7 months ago - By: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
Please enable JavaScript to continue using this application.